8 Analysts Assess Globus Medical: What You Need To Know
Analysts' ratings for Globus Medical (NYSE:GMED) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 3 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $105.62, along with a high estimate of $115.00 and a low estimate of $87.00. This upward trend is evident, with the current average reflecting a 13.36% increase from the previous average price target of $93.17.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of Globus Medical among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Saxon | Needham | Raises | Buy | $114.00 | $112.00 |
| David Saxon | Needham | Announces | Buy | $112.00 | - |
| Caitlin Cronin | Canaccord Genuity | Raises | Buy | $112.00 | $105.00 |
| Matt O'Brien | Piper Sandler | Raises | Overweight | $115.00 | $90.00 |
| Caitlin Cronin | Canaccord Genuity | Raises | Buy | $105.00 | $90.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $100.00 | $92.00 |
| Keith Hinton | Freedom Capital Markets | Announces | Hold | $87.00 | - |
| Drew Ranieri | Morgan Stanley | Raises | Overweight | $100.00 | $70.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Globus Medical. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Globus Medical compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Globus Medical's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
For valuable insights into Globus Medical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Globus Medical analyst ratings.
About Globus Medical
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
Globus Medical's Financial Performance
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Globus Medical's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 22.91% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Globus Medical's net margin is impressive, surpassing industry averages. With a net margin of 15.47%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Globus Medical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.74%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Globus Medical's ROA stands out, surpassing industry averages. With an impressive ROA of 2.37%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Globus Medical's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
How Are Analyst Ratings Determined?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.